STRATEGIES FOR STUDYING BRAIN DISORDERS
Congresos
Implications of Comorbidity for Etiology and Treatment of Neuropsychiatric Disorders
Mazagón (Huelva)
October 19 - 23 2005
The content of this congress, together with other contributions on the topic, are collected in vol. 8 of the series "Strategies for studying brain disorders"
PROGRAMME
- Tomas Palomo, Spain
Opening Remarks - German Berrios, UK.
Comorbidity and Psychiatric Nosology
S1. GENETIC VARIATION UNDERLYING COMORBIDITY
- Douglas Blackwood, UK
Common Genotypes in Schizophrenia and Depression - Janet Hoenicka, Spain
Genetic variants in Psychiatric Disorders - Kenneth Blum, USA
Genetic Variants underlying Reward Deficiency Syndrome - Tomás Palomo, Spain
Genetic Contributions to Psychopathic Traits in Alcoholic Patients - Isidro Ferrer, Spain
DNA chip technology in Brain Banks: Efficiency and Reliability for Neuropsychiatric Research
S2. NEURONAL SUBSTRATES OF COMORBIDITY IN ANIMAL MODELS
- Susan Totterdell, UK
The Anatomy of Synaptic Interactions in Cortical and Limbic Regions - Bita Moghaddam, USA
Shared Pathways that support Addictive and Schizophrenia –like Behaviors - Athina Markou, USA
Design of Animal Models and Treatments for Addiction and Depression Comorbidity - Peter Kalivas, UK
Signal Transduction Mechanisms in Addiction and Schizophrenia - Mark Geyer, USA
The Family of Sensorimotor Gating Disorders: Comorbidities or Diagnostic Overlaps? - Therese M. Jay, France
Stress, Frontal Synaptic Plasticity and Psychotropic Drugs
S3. MOVEMENT DISORDERS IN PSYCHOTIC STATES
- Trevor Archer, Sweden
Postnatal Iron Involvement in Motor Alterations pertaining to Psychosis-related Behaviour - Peter Riederer, Germany
Psychotics Stages in Parkinson´s Disease and Motor Symptoms in Schizophrenia: Basic Aspects - Moussa Youdim, Israel
Implications of Comorbidity for Etiology and Treament of Neurodegenerative Diseases with Multifunctional Drugs - Werner Schmidt, Germany
Behavioural Sensitization in Schizophrenia,Parkinson´s Disease and Dyskinesia
S4. IATROGENIC COMORBIDITY
- Richard J. Beninger, Canada
Cognitive Effects of Antipsychotic Medications - Michael Maes, Belgium
Immunological Effects of Antipsychotics - Richard M. Kostrzewa , USA
Haloperidol-Induced Tardive Dyskinesia inRats, its Persistence after Discontinuation of Haloperidol, and Effective Treatments - Abraham Weizman, Israel
Comorbidity of Schizophrenia and OCD: Clinical Aspects, Neurobiology and Treatment
S5. COGNITION LEARNING AND COMORBIDITY
- Klaus Ebmeier, UK
Cognitive Impairment in Major Depression (the fMRI perspective)? - Brian Leonard, Ireland
Changes in the Immune System in Depression and Dementia: Causal o Coincidental Effects? - José María Delgado, Spain
Experimental models for the Study of Cognitive Disorders - Martín Cammarota, Brazil
The consequences of Memory Expression - Ivan Izquierdo, Brazil
Further Learning moves Memory making Mechanisms from the Hippocampus to the Striatum
S6. COMORBIDITY IN ADDICTION WITH OTHER PSYCHIATRIC ILLNESSES
- Marta Torres, Spain
Importance of Clinical Diagnoses for Comorbidity studies - John Krystal, USA
Comorbidity between Schizophrenia and Addiction - Pierre Sokoloff, France
BDNF: an Etiological Factor in Schizophrenia and Drug Addiction - Alan I. Green, USA
Pharmacotherapy for Schizophrenia and Co-occurring Substance Use Disorders - Miguel Casas, Spain
Dual Diagnosys in Physicians - Cristine Barrowclough, UK
Psychological Approaches to working with Psychosis and Substance Misusing Clients
S7. IMPLICATIONS OF COMORBIDITY FOR ETIOLOGY AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS
- Antonio Lobo, Spain
Depressive Comorbidity in patients with Somatic Pathology - Henry Szechtman, Canada
Obsessive-compulsive Disorder as a Disturbance of Security Motivation. The Immune function in Schizophrenia - Vicente Molina, Spain
Neuroimaging Profiles, Typical and Atypical Antipsychotics and Disease Evolution - Tom G. Bolwig, Denmark
Epilepsy and Affective Disorder - Norbert Müller, Germany
The Immune function in Schizophrenia - Anthony Grace, USA
Disruption of Cortical-Amygdala Interaction as a substrate for Co-morbidtity - Joseph T. Coyle, USA
Glutamate Transmission as a Common Mechanism in Co-morbid Psycopathologies
- Tomás Palomo, Spain
Concluding Remarks
Fundación Cerebro y Mente
c/ General Oraa, 47 - 1º E 28006 Madrid, España
Telf: +34 91 561 1267 Fax: +34 91 564 1817
http://www.cermente.com
© 2009 Fundación Cerebro y Mente. Todos los derechos reservados.